Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 625-633

  Fiscus, Susan A ^c   Hughes, Michael D ^c   Lathey, Janet L ^a   Pi, Timothy ^c   Brooks Jackson, J ^c   Rasheed, Suraiya ^c   Elbeik, Tarek ^c   Reichman, Richard ^c   Japour, Anthony ^b   Byington, Roy ^c   Scott, Walter ^c   Griffith, Brigitte P ^c   Katzenstein, David A ^c   Hammer, Scott M ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; GAG PROTEIN; NUCLEOSIDE DERIVATIVE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION;

EID: 17344370610     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514248     Document Type: Article

References (29)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. N Engl J Med 1987;317:185-91.
2. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
3. Collier AC, Coombs RC, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786-93.
4. Chaisson RE, Leuther MD, Allain JP, et al. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Arch Intern Med 1988;148:2151-3.
5. Merigan TC, Skowron G, Bozzette S, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I-II study. Ann Intern Med 1989;110:189-94.
6. Fiscus SA, DeGruttola V, Gupta P, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995; 171:305-11.
7. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
8. Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996;10:859-65.
9. + lymphocyte count to progression to AIDS in the Department of Veterans Affairs Zidovudine Study. N Engl J Med 1996;334:426-31.
10. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
11. Griffith BP, Brett-Smith H, Kim G, et al. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis 1996;171:1252-5.
12. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
13. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019-30.
14. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
15. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
16. 3 (AIDS Clinical Trials Group 175). J Infect Dis 1998;177:617-24.
17. National Institutes of Health. ACTG virology manual for HIV laboratories, 3rd ed. Bethesda, MD: NIH, 1994; publication no. NIH 94-3828.
18. Japour A, Fiscus S, Arduino JM, et al. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32:2291-4.
19. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
20. DeGruttola V, Beckett LA, Coombs RW, et al. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. J Infect Dis 1994; 169:713-21.
21. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective. Validating surrogate markers: are we being naive? J Infect Dis 1997; 175:237-46.
22. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
23. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
24. St. Clair MH, Hartigan PM, Andrews JC, Vavro CL, Simberkoff MS, Hamilton JD. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1993; 6:891-7.
25. Zheng NN, McQueen PW, Hurren L, et al. Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine. J Infect Dis 1996;173:1092-6.
26. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic capacity of plasma HIV-1 RNA copy number in ACTG116A [abstract 230]. In: 2nd National Conference on Human Retroviruses and Related Infections, program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1995.
27. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA Panel. JAMA 1997;277:1962-9.
28. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic value of plasma HIV-1 RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 1996; 174:696-703.
29. Coombs RW, Welles SL, Hooper C, et al. Association of plasma HIV-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.